Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Q3 net loss widens to $20.8 million; cash totals $161.4 million

Negative Impact 3 of 5 earnings

Ovid Therapeutics reported third quarter 2026 results with no revenue, compared with $132 thousand a year earlier. The net loss widened to $20.8 million from $12.2 million, driven by research and development expenses that rose to $15.7 million from $5.9 million as the OV329 and OV4071 programs advanced. The company said its cash runway extends into 2029, though its net loss per share improved to $0.10 from $0.17 mainly because the weighted-average share count rose to about 203 million from about 71 million.

Key points

  • Net loss was $20.8 million for the quarter ended September 30, 2026, versus $12.2 million a year earlier.
  • Research and development expenses were $15.7 million, compared with $5.9 million in the prior-year quarter.
  • Cash, cash equivalents and marketable securities were $161.4 million at September 30, 2026, up from $90.4 million at December 31, 2025, with runway expected into 2029.
  • Topline data for OV329 photosensitivity study and OV4071 Phase 1 study are expected in the first quarter of 2027.

The filing

CompanyOvid Therapeutics Inc. (OVID)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:03 AM ET
Accession number0001628280-26-072494

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:11 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.